Aseptic Processing: A Primer - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Aseptic Processing: A Primer
PharmTech speaks to Ray O'Connor from the National Institute for Bioprocessing Research and Training (NIBRT) for an overview of aseptic processing.

Pharmaceutical Technology Europe


Environmental monitoring

Q PTE: What sort of environmental monitoring program need to be used in aseptic processing?

O'Connor: The goal of an environmental monitoring program is to provide meaningful information on the quality of the aseptic processing. Typical controls are for airborne particles and nonviable contaminant monitoring (i.e., to analyse the amount of microbes in the room). Viable contaminant monitoring of surfaces involves touching surfaces with agar plates. Viable monitoring of personnel and temperature–humidity monitoring are also typical controls to have in place.

Environmental monitoring must be done across all processing shifts (i.e., day and night). All floors, walls and equipment surfaces need to be tested. The location of the surfaces to be sampled, and the timing and frequency of the sampling, should be specified in writing, so that it is not just a random process, but rather, a risk-based process. It's also important for staff to ensure reproducible results.

The heating and ventilation and air conditioning (HVAC) unit should be under control of the building management system. This system controls the amount of air coming in to the cleanrooms and the differential pressure across the HEPA filters. If any changes are observed, actions and alerts should be raised to start an investigation and corrective–preventive action plan.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
27%
Breakthrough designations
9%
Protecting the supply chain
41%
Expedited reviews of drug submissions
9%
More stakeholder involvement
14%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
Source: Pharmaceutical Technology Europe,
Click here